MedTrace Logo

Concentrations of Remifentanil for Extubation

NCT02711904 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2016-03-17

No results posted yet for this study

Summary

Condition of the State: (terminated, recruiting, etc.) Terminated

Study Design: Main Objective:

Compare the frequency and intensity of coughing at the time of extubation with two infusions of remifentanil that predict a plasma concentration (PC) of 3 - 4 and 2 - 3 ng/ml, through the technique of target controlled anesthesia

Conditions

Interventions

DRUG

Extubation U

Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were: * 20 years old - 6.0 mcg/Kg/h * 30 years old - 5.7 mcg/Kg/h * 40 years old - 5.3 mcg/kg/h * 50 years old - 5.0 mcg/kg/h * 60 years old - 4.6 mcg/kg/h * 70 years old - 4.3 mcg/kg/h * 80 years old - 4.0 mcg kg/h.

DRUG

Extubation T

Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner: The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient. The remifentanil dose was adjusted according to the randomization: * 20 years old - 9.0 mcg/Kg/h * 30 years old - 8.5 mcg/Kg/h * 40 years old - 8.0 mcg/kg/h * 50 years old - 7.5 mcg/kg/h * 60 years old - 7.0 mcg/kg/h * 70 years old - 6.5 mcg/kg/h * 80 years old - 6.0 mcg kg/h.

Sponsors & Collaborators

  • Instituto Para Ninos Ciegos y Sordos del Valle del Cauca

    collaborator OTHER

  • Seganest

    lead OTHER

Principal Investigators

  • LUIS A TAFUR, MD · Seganest

  • Eduardo Lema, MD · Seganest

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-01-31
Completion
2012-07-31

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02711904 on ClinicalTrials.gov